Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene

Senquan Liu, Zhaohui Ye, Yongxing Gao, Chaoxia He, Donna W. Williams, Alison R Moliterno, Jerry L Spivak, He Huang, Linzhao Cheng

Research output: Contribution to journalArticle

Abstract

Activating point mutations in the MPL gene encoding the thrombopoietin receptor are found in 3%–10% of essential thrombocythemia (ET) and myelofibrosis patients. Here, we report the derivation of induced pluripotent stem cells (iPSCs) from an ET patient with a heterozygous MPL V501L mutation. Peripheral blood CD34+ progenitor cells were reprogrammed by transient plasmid expression of OCT4, SOX2, KLF4, c-MYC plus BCL2L1 (BCL-xL) genes. The derived line M494 carries a MPL V501L mutation, displays typical iPSC morphology and characteristics, are pluripotent and karyotypically normal. Upon differentiation, the iPSCs are able to differentiate into cells derived from three germ layers.

Original languageEnglish (US)
Pages (from-to)57-59
Number of pages3
JournalStem Cell Research
Volume18
DOIs
StatePublished - Jan 1 2017

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)
  • Developmental Biology
  • Cell Biology

Cite this